Resolian acquires China-based bioanalytical CRO Denali Medpharma

Published: 1-Nov-2023

Resolian, a global bioanalytical contract research organisation (CRO) specialising in drug metabolism and pharmacokinetics for small and large molecules, has acquired Denali Medpharma, a leading China-based bioanalytical CRO

Resolian now has bioanalysis laboratory operations in the US, UK, Australia and China. The company can initiate a project on four continents and easily transfer validated methods across labs, allowing therapeutic trials to extend to virtually any destination without changing bioanalytical CROs.
“The strategic addition of Denali will significantly enhance our capabilities and strengthen our position in the global market,” said Resolian CEO Patrick Bennett.

“Denali’s founders and core scientists are internationally recognised across pharmaceutical research and development analysis and we are particularly excited to add Denali’s oligo, mRNA, and liposomal expertise to Resolian’s portfolio of services."

"We look forward to leveraging our growing company’s strengths to continue driving innovation and creating lasting value for our clients and stakeholders.”

“The Denali team is thrilled to join Resolian,” said Denali CEO Min Meng, PhD

“Denali was founded by a group of US-trained bioanalytical experts in a state-of-the-art lab facility in China to provide exceptional service for domestic and international clients. We look forward to continuing this track record and offering even greater capabilities and trial flexibility as part of Resolian.”

You may also like